Abstract:A prognostic factor is any measure that is associated with the risk of future health outcomes in those with existing disease. Often, the prognostic ability of a factor is evaluated in multiple studies. However, meta-analysis is difficult because primary studies often use different methods of measurement and/or different cut-points to dichotomise continuous factors into 'high' and 'low' groups; selective reporting is also common. We illustrate how multivariate random effects meta-analysis models can accommodate multiple prognostic effect estimates from the same study, relating to multiple cut-points and/or methods of measurement. The models account for within-study and between-study correlations, which utilises more information and reduces the impact of unreported cut-points and/or measurement methods in some studies. The applicability of the approach is improved with individual participant data and by assuming a functional relationship between prognostic effect and cut-point to reduce the number of unknown parameters. The models provide important inferential results for each cut-point and method of measurement, including the summary prognostic effect, the between-study variance and a 95% prediction interval for the prognostic effect in new populations. Two applications are presented. The first reveals that, in a multivariate meta-analysis using published results, the Apgar score is prognostic of neonatal mortality but effect sizes are smaller at most cut-points than previously thought. In the second, a multivariate meta-analysis of two methods of measurement provides weak evidence that microvessel density is prognostic of mortality in lung cancer, even when individual participant data are available so that a continuous prognostic trend is examined (rather than cut-points).

Evaluation of Predictive Capacities of Biomarkers Based on Research Synthesis.

Medical diagnostic accuracy measures: an innovative approach based on the area under predictive values curves

Reporting and Methods in Developing Prognostic Prediction Models for Metabolic Syndrome: A Systematic Review and Critical Appraisal.

Sensitivity analysis for publication bias on the time-dependent summary ROC analysis in meta-analysis of prognosis studies

Measures of Performance and Clinical Superiority Thresholds for 'Test-and-treat' Predictive Biomarkers

Efficient screening of predictive biomarkers for individual treatment selection

Assessing clinical response in early oncology development with a predictive biomarker

Hybrid Design Evaluating New Biomarkers when There is an Existing Screening Test

Decision Curve Analysis: a Technical Note

Nonparametric Biomarker Based Treatment Selection With Reproducibility Data

Bayesian Solutions for Assessing Differential Effects in Biomarker Positive and Negative Subgroups

Covariate-specific Evaluation of Continuous Biomarker

Statistical Methods for Selective Biomarker Testing

Multivariate meta‐analysis of prognostic factor studies with multiple cut‐points and/or methods of measurement

Strategies for power calculations in predictive biomarker studies in survival data

Statistical Evaluation of Medical Tests

A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer

Ranking prognosis markers in cancer genomic studies.

Evaluating Prognostic Biomarkers for Survival Outcomes Subject to Informative Censoring.

Evaluating Markers for Selecting a Patient's Treatment.

Comparison of Diagnostic Markers with Repeated Measurements: a Non-Parametric ROC Curve Approach.